Procter & Gamble Health re-appoints S. Madhavan as Independent Director for five years

Procter & Gamble Health Limited's Board has approved the re-appointment of Mr. S. Madhavan as Independent Director for a term of five years effective November 15, 2026. The decision, taken at a Board meeting held on May 26, 2026, follows the recommendation of the company's Nomination & Remuneration Committee. The re-appointment is subject to the approval of the shareholders.

The company confirmed that Mr. Madhavan meets the criteria of independence laid down in Section 149 of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It was further affirmed that he is not debarred or disqualified from holding the office of a Director by any order from SEBI, the Ministry of Corporate Affairs, or any other statutory authority. Additionally, Mr. Madhavan does not hold any shares in the company.

The re-appointment is pursuant to the completion of Mr. Madhavan's first tenure. The company provided the requisite details in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Re-appointment Details

Detail	Information
Reason of Change	Re-appointment of Mr. S. Madhavan as Independent Director for a period of five years pursuant to completion of first tenure.
Date of Re-appointment	November 15, 2026
Term of Re-appointment	Five (5) years, i.e., from November 15, 2026 to November 14, 2031. Subject to approval of shareholders.
Relationship with Directors	None of the Directors of the Company are related to Mr. S. Madhavan.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+10.53%	+16.98%	+21.58%	+7.43%	+15.72%	+4.42%

Procter & Gamble Health Limited has announced the successful sale of immovable properties in Mumbai, generating a substantial profit for the healthcare company. The transaction was completed on April 30, 2026, marking a significant asset disposal for the organization.

Transaction Details

The company executed an indenture of sale for the disposal of certain immovable properties situated in Mumbai on April 30, 2026. This strategic move is expected to contribute positively to the company's financial performance.

Transaction Parameter:	Details
Transaction Date:	April 30, 2026
Property Location:	Mumbai
Expected Profit:	Approximately ₹32 crores
Transaction Type:	Sale of immovable properties

Regulatory Compliance

Procter & Gamble Health Limited has fulfilled its regulatory obligations by informing both major stock exchanges about this material transaction. The company submitted the required intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to:

BSE Limited (Scrip Code: 500126)
National Stock Exchange of India Limited (Scrip Code: PGHL)

Financial Impact

The property sale is projected to generate approximately ₹32 crores in profit for Procter & Gamble Health Limited. This significant gain from the disposal of real estate assets demonstrates the company's ability to optimize its asset portfolio and generate value from non-core holdings.

Corporate Authorization

The regulatory filing was digitally signed by Zeal Rupani, Company Secretary of Procter & Gamble Health Limited, on April 30, 2026, at 22:41:29 +05'30'. The formal communication ensures transparency and compliance with stock exchange requirements for material events that could impact investor decisions.